# Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)

> **NCT06313190** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 140 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **RADIATION:** Stereotactic body radiotherapy
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT06313190
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-05
- **Primary completion:** 2028-04-30
- **Final completion:** 2030-04-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2024-11-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06313190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06313190, "Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06313190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*